Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.82 million versus the consensus estimate of $9.39 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.